199796-52-6

Basic information

• Product Name: DHA-paclitaxel
• Synonyms: Paclitaxel 2'-(all-cis-4,7,10,13,16,19-docosahexaenoate);Taxoprexin;DHA-paclitaxel;TAXOPREXIN(P)
• CAS NO: 199796-52-6
• Molecular Formula: C69H81NO15
• Molecular Weight: 1164.37914
• Mol File: 199796-52-6.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• CAS DataBase Reference: DHA-paclitaxel(CAS DataBase Reference)
• NIST Chemistry Reference: DHA-paclitaxel(199796-52-6)
• EPA Substance Registry System: DHA-paclitaxel(199796-52-6)

Safety Data

• Hazardous Substances Data: 199796-52-6(Hazardous Substances Data)

Usage

Description

DHA-paclitaxel, also known as a fatty acid derivative of Paclitaxel, is an antineoplastic agent that has been modified to enhance its solubility and bioavailability. It is derived from hydrolyzable tannins found in various plant sources and has been extensively studied for its potential applications in cancer treatment. DHA-paclitaxel possesses unique properties that allow it to interact with biopolymers and macromolecules, making it a promising pharmaceutical candidate for various applications.

Uses

Used in Anticancer Applications:
DHA-paclitaxel is used as an anticancer agent for the treatment of various types of cancer, including lung, ovarian, breast, head and neck, and advanced forms of Kaposi's sarcoma. It works by stabilizing microtubules and inhibiting their disassembly, which leads to the arrest of cell division and ultimately, cell death. This makes DHA-paclitaxel a valuable tool in the fight against cancer.
Used in Pharmaceutical Research:
DHA-paclitaxel is also used in the study of the structure and function of microtubules, which are essential components of the cytoskeleton in eukaryotic cells. By understanding how paclitaxel interacts with tubulin, the protein subunit of microtubules, researchers can gain insights into the mechanisms of cell division and develop new strategies for cancer treatment.
Used in Drug Delivery Systems:
To overcome the limitations of traditional chemotherapy, novel drug delivery systems have been developed to enhance the applications and efficacy of DHA-paclitaxel against cancer cells. Various organic and metallic nanoparticles have been employed as carriers for DHA-paclitaxel delivery, aiming to improve its solubility, bioavailability, and therapeutic outcomes. These drug delivery systems can also help reduce the side effects associated with conventional chemotherapy by targeting the drug more specifically to cancer cells.